Protalix Biotherapeutics Inc
PLX1.780USD
+0.050+2.89%
Market hours （ET）Quotes delayed by 15 min
143.01MMarket Cap
23.75P/E TTM
More Details of Protalix Biotherapeutics Inc Company
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Protalix Biotherapeutics Inc Info
Ticker SymbolPLX
Company nameProtalix Biotherapeutics Inc
IPO dateSep 06, 2010
CEOBashan (Dror)
Number of employees207
Security typeOrdinary Share
Fiscal year-endSep 06
Address2 University Plaza
CityHACKENSACK
Stock exchangeNASDAQ OMX – NASDAQ Basic Amex
CountryUnited States of America
Postal code07601
Phone12016969345
Websitehttps://protalix.com/
Ticker SymbolPLX
IPO dateSep 06, 2010
CEOBashan (Dror)
Company Executives of Protalix Biotherapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
303.00K
+74.14%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Mr. Amos Bar Shalev
Mr. Amos Bar Shalev
Independent Director
Independent Director
--
--
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Dr. Shmuel (Muli) Ben-Zvi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Eliot Richard Forster, Ph.D.
Dr. Eliot Richard Forster, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Gilad Mamlok
Mr. Gilad Mamlok
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Dror Bashan
Mr. Dror Bashan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.28M
--
Dr. Aharon Schwartz, Ph.D.
Dr. Aharon Schwartz, Ph.D.
Independent Director
Independent Director
303.00K
+74.14%
Mr. Yaron Naos
Mr. Yaron Naos
Senior Vice President - Operations
Senior Vice President - Operations
207.30K
--
Ms. Gwen A. Melincoff
Ms. Gwen A. Melincoff
Independent Director
Independent Director
40.00
--
Dr. Pol F. Boudes, M.D.
Dr. Pol F. Boudes, M.D.
Independent Director
Independent Director
40.00
--
Mr. Mike Moyer
Mr. Mike Moyer
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
HIR Investments Ltd
5.86%
BlackRock Institutional Trust Company, N.A.
3.97%
Opaleye Management Inc.
3.21%
Bashan (Dror)
2.84%
Renaissance Technologies LLC
1.64%
Other
82.49%
Shareholders
Shareholders
Proportion
HIR Investments Ltd
5.86%
BlackRock Institutional Trust Company, N.A.
3.97%
Opaleye Management Inc.
3.21%
Bashan (Dror)
2.84%
Renaissance Technologies LLC
1.64%
Other
82.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
8.57%
Corporation
5.86%
Hedge Fund
4.97%
Individual Investor
4.29%
Investment Advisor/Hedge Fund
3.55%
Research Firm
0.18%
Venture Capital
0.11%
Bank and Trust
0.09%
Pension Fund
0.06%
Other
72.32%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
176
12.24M
15.35%
+846.09K
2025Q2
183
18.79M
23.60%
+3.26M
2025Q1
182
19.45M
25.30%
+4.26M
2024Q4
169
15.65M
21.26%
-1.03M
2024Q3
162
14.11M
19.17%
-5.41M
2024Q2
163
16.36M
22.25%
-4.44M
2024Q1
143
16.45M
23.43%
-4.40M
2023Q4
145
17.20M
24.67%
-3.21M
2023Q3
142
16.45M
24.08%
-6.46M
2023Q2
132
16.38M
24.76%
-4.13M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
HIR Investments Ltd
4.71M
5.91%
--
--
Apr 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
3.77%
+2.84M
+1741.73%
Jun 30, 2025
Bashan (Dror)
2.28M
2.86%
--
--
Apr 30, 2025
Renaissance Technologies LLC
1.62M
2.03%
+426.05K
+35.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
826.33K
1.04%
+826.33K
--
Jun 30, 2025
Rubin (Eyal)
660.91K
0.83%
+90.91K
+15.95%
Apr 30, 2025
Northern Trust Global Investments Limited
689.88K
0.87%
+6.58K
+0.96%
Jun 30, 2025
Stratos Wealth Partners, Ltd.
350.00K
0.44%
+3.60K
+1.04%
Jun 30, 2025
State Street Investment Management (US)
444.24K
0.56%
+148.14K
+50.03%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.03%
Franklin US Small Cap Multifactor Index ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares UltraPro Russell2000
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Avantis International Small Cap Equity ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
Franklin US Small Cap Multifactor Index ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Proportion0.01%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Avantis International Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Protalix Biotherapeutics Inc?
The top five shareholders of Protalix Biotherapeutics Inc are:
HIR Investments Ltd holds 4.71M shares, accounting for 5.91% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.00M shares, accounting for 3.77% of the total shares.
Bashan (Dror) holds 2.28M shares, accounting for 2.86% of the total shares.
Renaissance Technologies LLC holds 1.62M shares, accounting for 2.03% of the total shares.
Geode Capital Management, L.L.C. holds 826.33K shares, accounting for 1.04% of the total shares.
HIR Investments Ltd holds 4.71M shares, accounting for 5.91% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.00M shares, accounting for 3.77% of the total shares.
Bashan (Dror) holds 2.28M shares, accounting for 2.86% of the total shares.
Renaissance Technologies LLC holds 1.62M shares, accounting for 2.03% of the total shares.
Geode Capital Management, L.L.C. holds 826.33K shares, accounting for 1.04% of the total shares.
What are the top three shareholder types of Protalix Biotherapeutics Inc?
The top three shareholder types of Protalix Biotherapeutics Inc are:
HIR Investments Ltd
BlackRock Institutional Trust Company, N.A.
Opaleye Management Inc.
HIR Investments Ltd
BlackRock Institutional Trust Company, N.A.
Opaleye Management Inc.
How many institutions hold shares of Protalix Biotherapeutics Inc (PLX)?
As of 2025Q3, 176 institutions hold shares of Protalix Biotherapeutics Inc, with a combined market value of approximately 12.24M, accounting for 15.35% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -8.25%.
What is the biggest source of revenue for Protalix Biotherapeutics Inc?
In --, the -- business generated the highest revenue for Protalix Biotherapeutics Inc, amounting to -- and accounting for --% of total revenue.
